FOURTH QUARTER AND FULL YEAR RESULTS 2011
London, 2 February 2012 Revenue for the full year was down 2 percent at constant exchange rates (CER) at $33,591 million. -Strong double-digit sales growth at CER for Crestor, Seroquel XR and Symbicort; Emerging Markets revenue increased by 10 percent at CER in the fourth quarter and for the full year. -Revenue performance reflects the loss of nearly $2 billion of revenue from generic competition, as well as a further $1 billion lost to the impact of government price interventions. Core operating profit for the full year was down 4 percent at CER to $13,167 million. -Core